Component

Study-specific large neutral amino acid supplementation in PKU

Context-specific entity; species, compartment and exposure are stated on each claim.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. In a 16-person PKU crossover study, LNAA supplementation produced limited executive-function benefits and lowered plasma phenylalanine mainly when participants were not taking their usual medical product.

    Study-specific large neutral amino acid supplementation in PKU → Executive-function outcomes in the small PKU LNAA trial source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Four two-week crossover phases involving LNAA/placebo with or without medical product.
    limitations
    Small, short study; not a replacement recommendation for established PKU management.
    nutrient_topic
    L-Phenylalanine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · L-Phenylalanine
    plain_language
    A mixture can change outcomes, but the existing diet affects its added value.
    primary_references
    The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. · 2007 · https://pubmed.ncbi.nlm.nih.gov/17368065/ · DOI 10.1016/j.ymgme.2007.02.002

    L-Phenylalanine: transport, protein synthesis, cofactor recycling and cross-nutrient mechanisms (2026-09-19) · lines 206–212

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Four two-week crossover phases involving LNAA/placebo with or without medical product. · source_derived_draft · unverified_draft

    ## l-phenylalanine-lnaa-clinical-boundary A mixture can change outcomes, but the existing diet affects its added value. In a 16-person PKU crossover study, LNAA supplementation produced limited executive-function benefits and lowered plasma phenylalanine mainly when participants were not taking their usual medical product. Model: Four two-week crossover phases involving LNAA/placebo with or without medical product. Limitations: Small, short study; not a replacement recommendation for established PKU management. Evidence access: Primary abstract The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. · 2007 · https://pubmed.ncbi.nlm.nih.gov/17368065/ · DOI 10.1016/j.ymgme.2007.02.002
    Complete structured claim and evidence

  2. In ten adults with PKU, LNAA supplementation increased melatonin measures and urinary dopamine while phenylalanine itself did not significantly change.

    Study-specific large neutral amino acid supplementation in PKU → Melatonin and urinary dopamine markers during PKU LNAA supplementation source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Three three-week crossover periods; serum/urine melatonin, urinary dopamine and plasma amino-acid ratios.
    limitations
    Urinary dopamine and melatonin are surrogate readouts, not a direct demonstration of restored brain neurotransmitter concentrations.
    nutrient_topic
    L-Phenylalanine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · L-Phenylalanine
    plain_language
    A downstream marker can improve even when phenylalanine concentration stays similar.
    primary_references
    Large neutral amino acid supplementation increases melatonin synthesis in phenylketonuria: a new biomarker. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23164313/ · DOI 10.1016/j.jpeds.2012.10.015

    L-Phenylalanine: transport, protein synthesis, cofactor recycling and cross-nutrient mechanisms (2026-09-19) · lines 214–220

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Three three-week crossover periods; serum/urine melatonin, urinary dopamine and plasma amino-acid ratios. · source_derived_draft · unverified_draft

    ## l-phenylalanine-lnaa-monoamine-markers A downstream marker can improve even when phenylalanine concentration stays similar. In ten adults with PKU, LNAA supplementation increased melatonin measures and urinary dopamine while phenylalanine itself did not significantly change. Model: Three three-week crossover periods; serum/urine melatonin, urinary dopamine and plasma amino-acid ratios. Limitations: Urinary dopamine and melatonin are surrogate readouts, not a direct demonstration of restored brain neurotransmitter concentrations. Evidence access: Primary full text Large neutral amino acid supplementation increases melatonin synthesis in phenylketonuria: a new biomarker. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23164313/ · DOI 10.1016/j.jpeds.2012.10.015
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards